Acutus Medical said it secured $26.2 million in new funding for the cardiac mapping technology it’s developing to image and map atrial fibrillation hotspots.
San Diego-based Acutus said the proceeds will cover the finishing work on its AcQMap high-resolution imaging and mapping device and broaden its portfolio into diagnostic and therapeutic catheters and "additional new innovative therapeutic products," according to a press release.
"We are pleased to be working with top tier investors that share our passion to develop the AcQMap System but understand the importance of offering a complete portfolio of products to help physicians tailor patient treatment while being respectful of the financial pressure on healthcare systems worldwide," president & CEO Randy Werneth said in prepared remarks. "Completion of this round of financing provides us with the opportunity to expand our product portfolio in many ways and continue to innovate and validate our core product, the AcQMap System."
Acutus announced a $28 million Series B round in August 2013. Investors in the San Diego-based company include GE Ventures, OrbiMed Healthcare Fund Management, Index Ventures and Advent Life Sciences.
Atrial fibrillation is an uncontrollable, rapid heartbeat that can lead to stroke or heart failure, with some 10 million people globally suffering from the condition. Acutus said its device gives physicians a real-time, 3D view to locate the precise source of an arrhythmia.
In May, Acutus won CE Mark approval in the European Union for a 3D diagnostic imaging and dipole density mapping catheter component.